🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Ireland Needs 46,000 More Digital Specialists by 2030, EGFSN Report Warns ◆ Project Management Failures: Lessons for Healthcare ◆ FDA Approves Lilly's Weekly Insulin Onswik to Rival Awiqli ◆ WeBuild Programme: 50+ Women-Led Ventures and How to Apply ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆
Clinical Trials in Germany / NCT01913938
Recruiting Observational

Hemophagocytosis in Critically Ill Adult Patients

NCT01913938 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Ulm
Phase
Observational
Started
2013-07
Last updated
2024-01-17

Condition(s) studied

Hemophagocytosis

Study summary

The purpose of the study is to find out whether non-responsiveness to therapeutic recombinant human granulocyte colony-stimulation factor (rhG-CSF) is associated with hemophagocytosis in critically ill adult patients with cytopenias.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * age \> 18 years * critically ill adult patients * leukopenia and thrombocytopenia * rhG-CSF therapy Exclusion Criteria: * life expectancy \< 24 hours * inclusion in other studies * trauma patients with reanimation on scene or immediately dying on hospital admission * pregnancy * hematologic disorder, malignancy * high dose corticosteroid treatment or chemotherapy

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Department of Anaesthesiology, University Hospital Ulm Ulm Germany Recruiting
Department of Internal Medicine III, Comprehensive Infectious Disease Center, University Hospital Ulm, Germany Ulm Germany Recruiting

More University of Ulm trials in Germany

Impact of Thyroid Hormones on Human Glucose and Energy Metabolism Recruiting
Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy Recruiting
Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas Recruiting
German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm) Recruiting
Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01913938 on ClinicalTrials.gov ↗ ← All trials in Germany